Tech Center 1600 • Art Units: 1642 1671
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | Non-Final OA | Genentech, Inc. |
| 18178086 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF | Non-Final OA | AMGEN INC. |
| 17609363 | MODULATING ANTIBODY EFFECTOR FUNCTIONS | Final Rejection | AMGEN INC. |
| 17281025 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Non-Final OA | NORTH CAROLINA STATE UNIVERSITY |
| 18247226 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17762576 | Quantitative Spatial Profiling for LAG-3 Antagonist Therapy | Final Rejection | Bristol-Myers Squibb Company |
| 17295747 | METHODS OF OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS | Final Rejection | Board of Regents, The University of Texas System |
| 17260428 | DETERMINING RESPONDERS TO INFLAMMATION TREATMENT | Non-Final OA | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 19046030 | Antibody-Drug Conjugates Targeting uPARAP Comprising Exatecan Derivatives | Final Rejection | ADCENDO APS |
| 17925574 | B7H3-TARGETING PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18186869 | METHOD OF TARGETING ONCOLYTIC VIRUSES TO TUMORS | Final Rejection | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 17460986 | System and Process for Production of Isotopes and Isotope Compositions | Non-Final OA | Battelle Memorial Institute |
| 18471357 | Chimeric Antigen Receptor Specific for Folate Receptor 1 | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18034037 | ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS | Non-Final OA | Vrije Universiteit Brussel |
| 18012900 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 17435159 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS | Non-Final OA | Cedars-Sinai Medical Center |
| 17767398 | CANCER COMBINATION TREATMENTS USING ANTI-STAT3 NUCLEIC ACID CONJUGATES | Final Rejection | CITY OF HOPE |
| 17262105 | TARGET CELL SPECIFIC CYTOSOL-PENETRATING ANTIGEN-BINDING MOLECULES | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18004618 | COMPOSITIONS COMPRISING ANTIBODIES TO HUMAN IDO-2 | Non-Final OA | Lankenau Institute for Medical Research |
| 18245114 | ANTIBODIES TARGETING HUMAN CLAUDIN 18.2 AND USES THEREOF | Non-Final OA | Nanjing GenScript Biotech Co., Ltd. |
| 18032086 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18011801 | COMBINATION THERAPY COMPRISING ANTI-CD137 ANTIBODIES | Final Rejection | Adagene PTE. LTD. |
| 17773223 | HALF-LIFE EXTENSION DRUG AND LIBRARY THEREOF, AND PREPARATION METHOD AND APPLICATION THEREOF | Final Rejection | ASSEMBLY MEDICINE. LLC |
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | Non-Final OA | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
| 17798879 | PROCESS FOR SITE-SPECIFIC MODIFICATION OF AN ANTIBODY | Final Rejection | Orano Med |
| 17585356 | TREATMENT OF KIDNEY FAILURE USING EX VIVO REPROGRAMMED IMMUNE CELLS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18030928 | ANTI-TROP-2 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF OR MUTANT THEREOF, AND MEDICAL USE THEREOF | Non-Final OA | Jiangsu Hansoh Pharmceutical Group Co., Ltd. |
| 17280403 | ANTIBODY COMPOSITION | Final Rejection | Kyowa Kirin Co., Ltd. |
| 17413965 | IMPROVED CELL-TARGETING BINDING MOLECULE | Non-Final OA | Sapreme Technologies B.V. |
| 18024801 | EXTRACELLULAR VESICLE EXPRESSING CYTOKINE AND ANTIBODY, METHOD FOR PRODUCING SAME, AND USE THEREOF | Final Rejection | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FUNDATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy